RecruitingPhase 4NCT07022496
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial
Sponsor
Ain Shams University
Enrollment
120 participants
Start Date
Apr 26, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Caffeine extracted from green tea to abort acute attack of Migraine
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria1
- Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.
Exclusion Criteria1
- Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCaffeine (200 mg)
caffeine tablets
DRUGtriptans
Sumatriptan
DRUGNSAID (Nonsteroidal anti-inflammatory drugs)
Aspirin 250 mg, 81 mg, 75 mg
DRUGParacetamol (acetaminophen)
Paracetamol 250 mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07022496
Related Trials
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT0697205623 locations
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313149 locations
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT0515639890 locations
Mind Body Balance for Pediatric Migraine
NCT047156852 locations
MMA Embolization for Refractory Chronic Migraine
NCT067358337 locations